Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed No phase listed Observational

Optimizing the Tobacco Cessation Clinical Decision Support Tool.

NCT03714191
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Patient Outcomes, Billing documentation, Regulatory
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years and older
Enrollment
54,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

NCT02542384
View directory record Official record
Conditions
Post Abdominal Surgery Pain
Interventions
CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

NCT07344558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
MNKD-201(Nintedanib DPI), Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fresno, California • Palm Springs, California • Doral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 23, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 23, 2026, 2:50 PM EDT
Terminated Not applicable Interventional

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

NCT02479906
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Deep TMS System, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

NCT01188304
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, aspirin, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

NCT04610047
View directory record Official record
Conditions
Influenza, Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

NCT01215149
View directory record Official record
Conditions
HIV Infections
Interventions
Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MEDI-557 Adult Dosing

NCT01562938
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI-557
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

NCT01156792
View directory record Official record
Conditions
Asthma
Interventions
FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 23, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Recruiting Phase 3 Interventional

Brexanolone Lifting Outcomes Of Moms

NCT07822321
View directory record Official record
Conditions
Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
Interventions
LPCN 1154A, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Canoga Park, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

NCT04781816
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Cooper City, Florida • Charlotte, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

NCT00446433
View directory record Official record
Conditions
Crohn's Disease
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

NCT02691247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
CLBS03 Low Dose, CLBS03 High Dose, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

NCT04238364
View directory record Official record
Conditions
Healthy Volunteers
Interventions
EI-1071, Placebo
Drug
Lead sponsor
Elixiron Immunotherapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

NCT00738699
View directory record Official record
Conditions
Ovarian Cancer
Interventions
MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 23, 2026, 2:50 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of OsrhAAT or Placebo in Healthy Volunteers

NCT05315921
View directory record Official record
Conditions
Emphysema Secondary to Congenital AATD
Interventions
OsrhAAT 1 mg/kg IV, OsrhAAT 3 mg/kg IV, OsrhAAT 10 mg/kg IV, OsrhAAT 20 mg/kg IV, OsrhAAT 40 mg/kg IV, OsrhAAT 60 mg/kg IV
Drug
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCT03160521
View directory record Official record
Conditions
Acute Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg, Placebo of Risperidone ISM
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Rogers, Arkansas • Cerritos, California • Garden Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 23, 2026, 2:50 PM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

NCT07226258
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
SL1002, Normal Saline
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Roseville, California • San Diego, California • Greenwood Village, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 2:50 PM EDT